Hospitals Challenge Upcoming 340B Rebate Overhaul in Court
The American Hospital Association, safety-net hospitals, and the Maine Hospital Association sued over changes to the 340B drug discount program set to take effect in January 2027. The new system would require hospitals to pay full drug prices and seek rebates afterward, which hospitals say will cost more than $1 billion and burden safety-net care. Drugmakers argue the program has been exploited and lacks oversight.
The suit was filed by the American Hospital Association, four safety-net hospitals, and the Maine Hospital Association against the Trump administration. Under current rules, eligible hospitals receive discounts before dispensing drugs—roughly 13% for generics and 23% for brands. The replacement, scheduled for January 2027, would make them buy at standard prices and claim rebates afterward; plaintiffs want the policy voided and prior arrangements restored.
Federal data show 340B-covered entities spent $100 billion on program drugs in 2025, up from $81.4 billion in 2024 and $66.3 billion in 2023. The hospital association estimates the rebate model could add over $1 billion in yearly administrative costs.
The dispute may affect patients at rural, low-income, and underserved hospitals if new upfront costs and paperwork divert resources from services. Safety-net providers could face cash-flow strain, while drugmakers may gain stronger oversight. Patients might see changes in access to medications or support programs, though outcomes depend on court action and how rebates work in practice.